title: [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
abstract: Treatment of nontuberculous mycobacterial infection should be carried out by the chemotherapeutic regimens most suitable for each species. We performed in-vitro susceptibility tests for various species and determined the probability in which the mycobacteria of each species are inhibited by blood concentrations attainable by the dosages usually used. From such determinations, the following regimens have been recommended: 1) M. avium-M. intracellulare complex, Rifampicin + Enviomycin + Ethambutol; 2) M. kansasii, Ofloxacin + Enviomycin + Rifampicin; 3) M. szulgai, Enviomycin - Ethambutol + Isoniazid; 4) M. fortuitum, Ofloxacin. The effectiveness of the treatment of the infection caused by M. avium complex is less than 15% even using the above regimen, while it is high in the treatment of infections caused by M. kansasii and M. szulgai. There are no effective regimens for the treatment of infection caused by M. chelonae or M. simiae. The above recommendations are useful in practice, because, at present, reliable susceptibility testing of nontuberculous mycobacteria is not yet done commonly.
authors.affiliation: Department of Microbiology, Fujita-Gakuen Health University Medical School, Aichi, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Tsukamura
authors.forename: S
authors.initials: S
authors.lastname: Yamori
mesh_terms: D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use; D004776:Enviomycin / Q000494:pharmacology* / Q000627:therapeutic use; D004977:Ethambutol / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology* / Q000627:therapeutic use; D009161:Mycobacterium / Q000187:drug effects*; D009164:Mycobacterium Infections / Q000188:drug therapy*; D015242:Ofloxacin / Q000494:pharmacology* / Q000627:therapeutic use; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use; D014756:Viomycin / Q000494:pharmacology*
chemical_list: D004977:Ethambutol; D015242:Ofloxacin; D007538:Isoniazid; D012293:Rifampin; D004776:Enviomycin; D014756:Viomycin